Galeri AG was founded by a medical doctor turned entrepreneur whose personal journey shaped the company’s mission. Growing up, she witnessed her father struggle with high myopia and the profound limitations it placed on his life — from restricted career opportunities to giving up activities he loved, like driving and playing golf. Although a treatment existed, the risk of blindness delayed him from pursuing it until later in life. When he finally underwent the procedure, his confidence and independence were instantly restored.

This transformation inspired our founder to focus her work on vision-threatening diseases during her time as a Visiting Scholar in Translational Medicine at Stanford University. With a deep understanding of the patient perspective, she recognized a critical need: to overcome the risks, burdens, and adherence challenges of injection-based therapies.

At the same time, ophthalmologists and formulation scientists in Texas were addressing the same issue. Their pioneering research led to the development of an antibody anti-aggregation formulation that made topical delivery possible, and their results — published in 2024 — demonstrated potential not only for ophthalmology but also for pulmonary disease and broader antibody-based applications.

Building on this foundation, Galeri AG is dedicated to advancing and sharing this breakthrough with the global research community. We provide access to our novel formulation, support collaboration and co-publication, and partner with scientists and developers to explore new therapeutic frontiers.”

Our Mission is to facilitate researchers and drug developers to unlock the full potential of antibody therapies using a novel reagent formulation.